O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Vice President - Sales & Marketing, Nephrology

Full-Time
$336.7k - $484k/yr+ Incentive opportunity
Expert
Bachelor's, Master's, MBA
Remote in USA
Remote
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree, preferably in a business, scientific, or analytical discipline such as marketing, pharmacology, biology, engineering, or mathematics; an MBA or other related graduate degree is preferred.
  • At least 15 years of cross-functional industry experience in commercial life sciences, pharmaceuticals, biotechnology, or a related industry, including engagement with key healthcare ecosystem players such as payers and health systems.
  • At least 10 years of experience in pharmaceutical marketing, product management, or a related industry.
  • Previous account management experience, including developing and implementing account plans for health ecosystem players such as health systems or hospitals, is a strong plus.
  • Previous experience building a positive, accountable, highly engaged culture.
  • Ability to synthesize information from multiple sources, generate insights, and identify underlying patterns and themes in a complex, multifaceted environment.
  • Ability to operate autonomously in a dynamic, ambiguous environment undergoing transformation.
  • Ability to coordinate a cross-functional team, align members around a common vision, and facilitate collaboration across organizational boundaries.
  • Ability to develop strategy in a complex stakeholder environment, including contracting strategy, administration, and pull-through.
  • Previous experience managing a complex profit-and-loss responsibility and demonstrating strong financial acumen.
  • Experience coaching, training, or mentoring peers or others to help them meet or exceed goals and achieve their full potential in role.
  • Previous field sales management and/or marketing experience in the biotechnology, pharmaceutical, or related industry.
  • Previous experience leading broad organizational change initiatives that improved performance.
  • Strong understanding of industry legal, regulatory, and compliance requirements.
  • Ability to remain focused on strategic objectives, uphold high performance standards, and lead change.
  • Ability to make decisions that consider long-term impacts on customers, patients, employees, and the business.
  • Ongoing focus on the needs of customers and key stakeholders.
  • Ability to communicate clearly and respectfully and influence stakeholders at all levels.
  • Ability to value others' perspectives and collaborate across diverse partnerships.
  • Active participation in professional development.
Responsibilities
  • Develop and execute the brand's long-term commercial strategy in alignment with business unit objectives and patient needs.
  • Establish annual and multi-year strategic plans that drive sustainable growth, patient impact, and business performance.
  • Serve as the primary commercial leader and strategic advisor for the brand within the organization.
  • Assess market dynamics, competitive trends, customer insights, and emerging opportunities to optimize brand performance.
  • Lead lifecycle planning and identify opportunities to expand the treated patient population and maximize long-term value.
  • Serve on the Nephrology, Immunology and Rare Disease business unit leadership team.
  • Provide executive leadership and oversight of sales, marketing, commercial scientific communications, and customer engagement activities.
  • Align brand strategy, field execution, customer engagement, and business objectives.
  • Oversee integrated omnichannel marketing programs, promotional strategies, and customer engagement initiatives.
  • Ensure commercial activities are executed effectively and comply with legal, regulatory, and company requirements.
  • Optimize launch performance and accelerate brand growth.
  • Evaluate launch and business performance metrics to improve adoption, account penetration, patient starts, and market share.
  • Refine customer segmentation, targeting, and engagement strategies using marketplace insights and evolving customer needs.
  • Identify and address barriers to adoption across patient, provider, and access journeys.
  • Drive initiatives that increase disease awareness, accelerate patient identification, and optimize referral pathways.
  • Partner with patient advocacy organizations, key opinion leaders, and centers of excellence to strengthen the rare disease ecosystem.
  • Ground commercial strategies in an understanding of patient, caregiver, and healthcare provider needs.
  • Champion patient-centered approaches that improve outcomes and treatment access.
  • Achieve revenue, market share, profitability, and operating income objectives.
  • Lead annual business planning, forecasting, and resource allocation processes.
  • Monitor commercial performance and adjust strategies to achieve business objectives.
  • Partner with Finance to manage budgets, investments, and financial performance.
  • Establish performance metrics and accountability measures across the commercial organization.
  • Partner with Medical Affairs, Market Access Strategy and Market Access, Patient Services, Regulatory, Legal, Compliance, Finance, and other matrix teams to deliver integrated solutions and optimize profit-and-loss performance.
  • Support access and reimbursement strategies that optimize patient access and treatment adoption.
  • Translate customer insights into recommendations that support lifecycle management and future growth opportunities.
  • Align commercial objectives with broader organizational priorities.
  • Build and lead a high-performing commercial organization focused on accountability, innovation, collaboration, and patient impact.
  • Recruit, develop, and retain commercial talent.
  • Create development plans and succession pathways for future leaders.
  • Foster a culture of continuous learning, engagement, and execution excellence.
  • Model the organization's values, ethics, and compliance standards.
Desired Qualifications
  • An MBA or other related graduate degree.
  • Previous account management experience, including developing and implementing account plans for health ecosystem players such as health systems or hospitals.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.